资讯
Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.
The pharmaceutical giant will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S.
Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.
Merck has launched construction of a $1 billion biologics facility in Wilmington, set to become the U.S. production hub for ...
9 小时on MSN
Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...
Health-care companies rose amid mixed earnings. Pfizer reaffirmed its outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker looks to turn around its business ...
According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 construction jobs expected on the job site. The laboratory component of the new site ...
Officials with Merck Biopharmaceutical Company broke ground on a new, 470,000 square foot biologics center at the Chestnut ...
The Detroit automaker's net income slid 6.6% in the first quarter on weaker sales of highly profitable trucks and SUVs. Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss ...
It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.
Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...
U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果